Search Result

Results for "

prioritization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Biochemical Assay Reagents (2) Dopamine Receptor (1) Drug Metabolite (1) Glycosyltransferase (1) Phytohormone (1) Reference Standards (1)
By Research Areas:	Infection (1) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1096

Etamivan Ethamivan; N,N-Diethylvanillamide	Biochemical Assay Reagents	Neurological Disease
Etamivan (Ethamivan; N,N-Diethylvanillamide) is an orally active respiratory stimulant. Ethamivan regulates breathing patterns by directly stimulating the medullary respiratory center, prioritizing increased breathing depth rather than frequency. Etamivan can be used in the research of barbiturate overdose and chronic obstructive pulmonary disease .

HY-N1033

12-Hydroxyjasmonic acid	Phytohormone Drug Metabolite Glycosyltransferase	Infection
12-Hydroxyjasmonic acid is a metabolite of Jasmonic acid (HY-122464A) and an inducer of defense responses. 12-Hydroxyjasmonic acid can be isolated from potato leaflets. During the response of sugar beet plants to Cercospora beticola infection, 12-Hydroxyjasmonic acid is released through deglycosylation of its glucoside form and participates in the Jasmonic acid-mediated defense signaling pathway. 12-Hydroxyjasmonic acid mediates changes in source-sink relationships during pathogen infection, prioritizing the activation of defense processes over growth processes. 12-Hydroxyjasmonic acid serves as a substrate for salicylic acid Glycosyltransferases in tobacco and rice. 12-Hydroxyjasmonic acid can induce leaflet closure in Samanea saman. 12-Hydroxyjasmonic acid acts as a potato tuber-inducing substance. 12-Hydroxyjasmonic acid does not induce protoplast shrinkage in extensor motor cells of Samanea saman. 12-Hydroxyjasmonic acid can be used in studies related to brown spot disease .

HY-B1096R

Etamivan (Standard) Ethamivan (Standard); N,N-Diethylvanillamide (Standard)	Biochemical Assay Reagents Reference Standards	Neurological Disease
Etamivan (Ethamivan; N,N-Diethylvanillamide) (Standard) is the analytical standard of Etamivan (HY-B1096). This product is intended for research and analytical applications. Etamivan is an orally active respiratory stimulant. Ethamivan regulates breathing patterns by directly stimulating the medullary respiratory center, prioritizing increased breathing depth rather than frequency. Etamivan can be used in the research of barbiturate overdose and chronic obstructive pulmonary disease.

HY-401563

5-HT2A antagonist 4 methanesulfonate	5-HT Receptor Dopamine Receptor	Neurological Disease
5-HT2A antagonist 4 methanesulfonate (Example 29) is a dopamine D2 receptor and serotonin 5HT2A receptor antagonist. 5-HT2A antagonist 4 methanesulfonate can be used for the study of central nervous system diseases .

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library	2,817 compounds
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 2,817 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Anti-Ovarian Cancer Compound Library

2,817 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,817 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.